AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1828764 — intervention group
Group type: EXPERIMENTAL
Intervention: doxazosin
Number of subjects: 84
Study 1828764 — intervention group
Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 84
Study 6286089 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy to the chest (RC), 3000 rad in two weeks
Number of subjects: 0
Study 6286089 — intervention group
Group type: COMPARATOR
Intervention: No radiotherapy to the chest (Control)
Number of subjects: 0
Study 6286089 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT)
Number of subjects: 0
Study 6286089 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy to the chest (RC)
Number of subjects: 0
Study 6286089 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with periodic reinductions
Number of subjects: 0
Study 31256660 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct lateral approach
Number of subjects: 150
Study 31256660 — intervention group
Group type: COMPARATOR
Intervention: Anterolateral approach
Number of subjects: 150
Study 28235510 — intervention group
Group type: EXPERIMENTAL
Intervention: Right stellate ganglion block (RSGB) using 10mL of 1% lidocaine.
Number of subjects: 60
Study 28235510 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo).
Number of subjects: 60
Study 24354454 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fluoride toothpaste (5000 ppm F)
Number of subjects: 130
Study 22038532 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychological intervention (two 1-hour sessions in participants' homes)
Number of subjects: 58
Study 22038532 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus researcher contact (Control)
Number of subjects: 58
Study 19222415 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (100 units)
Number of subjects: 12
Study 19222415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17612359 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical high‐velocity low‐amplitude (HVLA) thrust manipulation
Number of subjects: 15
Study 17612359 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham‐manual application)
Number of subjects: 15
Study 17612359 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 15
Study 14725517 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (n = 109)
Number of subjects: 220
Study 14725517 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture (n = 111)
Number of subjects: 220
Study 11166751 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chloroprocaine
Number of subjects: 82
Study 11166751 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 82
Study 9038494 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair
Number of subjects: 140
Study 9038494 — intervention group
Group type: COMPARATOR
Intervention: Open hernia repair
Number of subjects: 140
Study 9038494 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative assessment
Number of subjects: 140
Study 9038494 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative assessment at 3 months
Number of subjects: 140
Study 9038494 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative assessment compared to population norms
Number of subjects: 140
Study 8294223 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 25 mg/day for 4 weeks followed by 50 mg/day for 4 weeks
Number of subjects: 20
Study 8294223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3505536 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand A salbutamol metered-dose inhaler (MDI)
Number of subjects: 31
Study 3505536 — intervention group
Group type: COMPARATOR
Intervention: Brand B salbutamol metered-dose inhaler (MDI)
Number of subjects: 31
Study 29525611 — intervention group
Group type: EXPERIMENTAL
Intervention: Purple potato chips
Number of subjects: 11
Study 29525611 — intervention group
Group type: COMPARATOR
Intervention: White potato chips
Number of subjects: 11
Study 29525611 — intervention group
Group type: EXPERIMENTAL
Intervention: Potato phenolic extracts (PPE)
Number of subjects: 11
Study 29525611 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 11
Study 27741230 — intervention group
Group type: EXPERIMENTAL
Intervention: boceprevir
Number of subjects: 50
Study 27741230 — intervention group
Group type: COMPARATOR
Intervention: telaprevir
Number of subjects: 50
Study 25054392 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol PR (100 - 250 mg bid)
Number of subjects: 496
Study 25054392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 496
Study 25054392 — intervention group
Group type: COMPARATOR
Intervention: Morphine CR (40 - 100 mg bid)
Number of subjects: 496
Study 25054392 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol PR
Number of subjects: 496
Study 25054392 — intervention group
Group type: COMPARATOR
Intervention: Morphine CR
Number of subjects: 496
Study 22437996 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating-platform tibial component
Number of subjects: 240
Study 22437996 — intervention group
Group type: COMPARATOR
Intervention: All-polyethylene fixed-bearing tibial component
Number of subjects: 240
Study 22437996 — intervention group
Group type: COMPARATOR
Intervention: Modular-metal-backed fixed-bearing tibial component
Number of subjects: 240
Study 22437996 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 240
Study 21254596 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloferon with lamivudin
Number of subjects: 0
Study 21254596 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-interferon with cycloferon
Number of subjects: 0
Study 21254596 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloferon
Number of subjects: 0
Study 18460985 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised resistance exercise
Number of subjects: 242
Study 18460985 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise
Number of subjects: 242
Study 18460985 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 242
Study 16192367 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg qid for 2 days)
Number of subjects: 30
Study 16192367 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (25 mg once a day for 5 days)
Number of subjects: 30
Study 14646457 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10547110 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyloric ratio measurement (wall thickness/pyloric diameter)
Number of subjects: 87
Study 10547110 — intervention group
Group type: COMPARATOR
Intervention: Standard criteria for diagnosing hypertrophic pyloric stenosis
Number of subjects: 87
Study 8625171 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 5-FU (1000 mg/m2, days 1-4) with bolus FA (200 mg/m2, days 1-4)
Number of subjects: 80
Study 8625171 — intervention group
Group type: COMPARATOR
Intervention: Bolus 5-FU (375 mg/m2, days 1-5) with bolus FA (200 mg/m2, days 1-5)
Number of subjects: 80
Study 2404768 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (30 mg q.i.d. orally for 14 days)
Number of subjects: 52
Study 2404768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 2404768 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 52
Study 7362504 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate
Number of subjects: 20
Study 7362504 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% epinephrine hydrochloride
Number of subjects: 20
Study 31859528 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrescent intensity training (TR; n=9)
Number of subjects: 17
Study 31859528 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON; n=8)
Number of subjects: 17
Study 29260401 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exercise protein supplementation made from cow's milk (13 g of proteins)
Number of subjects: 9
Study 29260401 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exercise protein supplementation made from rice milk (isocaloric protein-free beverage)
Number of subjects: 9
Study 29260401 — intervention group
Group type: COMPARATOR
Intervention: Post-exercise water (control)
Number of subjects: 9
Study 27565830 — intervention group
Group type: COMPARATOR
Intervention: Home-based vegetable gardening intervention (Harvest for Health) with one-on-one mentorship over 12 months.
Number of subjects: 128
Study 25116312 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia assisted instruction for 3 weeks
Number of subjects: 96
Study 25116312 — intervention group
Group type: COMPARATOR
Intervention: Control group (no multimedia instruction)
Number of subjects: 96
Study 25116312 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia assisted instruction
Number of subjects: 96
Study 22872695 — intervention group
Group type: EXPERIMENTAL
Intervention: LiFE programme (n=107)
Number of subjects: 317
Study 22872695 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured programme (n=105)
Number of subjects: 317
Study 22872695 — intervention group
Group type: COMPARATOR
Intervention: Sham control programme (n=105)
Number of subjects: 317
Study 20659368 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive use at three episodes of sexual intercourse
Number of subjects: 435
Study 20659368 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal, putting on a condom before ejaculation, or non-use
Number of subjects: 435
Study 20659368 — intervention group
Group type: EXPERIMENTAL
Intervention: Method use suggestive of greater risk-taking behaviour
Number of subjects: 435
Study 20659368 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with greater pregnancy risk-taking behaviour
Number of subjects: 435
Study 18361231 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibial rotational alignment determined by medical 1/3 of tibial tubercle (Group A)
Number of subjects: 60
Study 18361231 — intervention group
Group type: COMPARATOR
Intervention: Tibial rotational alignment determined by medial border of tibial tubercle at 0‐9 degrees varus (Group B)
Number of subjects: 60
Study 16238896 — intervention group
Group type: EXPERIMENTAL
Intervention: IV paracetamol 1 g
Number of subjects: 38
Study 16238896 — intervention group
Group type: EXPERIMENTAL
Intervention: IV metamizol 1 g
Number of subjects: 38
Study 12151921 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at 600 ng/ml
Number of subjects: 11
Study 12151921 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at 1000 ng/ml
Number of subjects: 11
Study 10208787 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme (ACE) inhibitors
Number of subjects: 1825
Study 10208787 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 1825
Study 10208787 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 1825
Study 10208787 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmics
Number of subjects: 1825
Study 10208787 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 1825
Study 10208787 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 1825
Study 10208787 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulants
Number of subjects: 1825
Study 10208787 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelets
Number of subjects: 1825
Study 7838947 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based programs to increase fruit and vegetable consumption
Number of subjects: 9
Study 2220582 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear pacemakers (VOO)
Number of subjects: 132
Study 2220582 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear pacemakers (all types)
Number of subjects: 132
Study 2220582 — intervention group
Group type: COMPARATOR
Intervention: Lithium-chemistry demand pacemakers (VVI)
Number of subjects: 132
Study 677431 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (0.80 mcg/kg body weight/10 min) and Flunitrazepam (1 mg)
Number of subjects: 0
Study 677431 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.05 mg) administered postoperatively
Number of subjects: 0
Study 677431 — intervention group
Group type: COMPARATOR
Intervention: Enflurane (no opiate)
Number of subjects: 0
Study 677431 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine (premedication)
Number of subjects: 0
Study 7104154 — intervention group
Group type: EXPERIMENTAL
Intervention: pindolol 10 mg three times daily for 4 weeks
Number of subjects: 18
Study 7104154 — intervention group
Group type: COMPARATOR
Intervention: metoprolol 100 mg three times daily for 4 weeks
Number of subjects: 18
Study 7104154 — intervention group
Group type: EXPERIMENTAL
Intervention: both groups
Number of subjects: 18
Study 7104154 — intervention group
Group type: COMPARATOR
Intervention: metoprolol
Number of subjects: 18
Study 31049085 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac 0.9 mg/Kg
Number of subjects: 100
Study 31049085 — intervention group
Group type: COMPARATOR
Intervention: Intravenous nalbuphine 0.25 mg/Kg
Number of subjects: 100
Study 28930797 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate everolimus (EVR-I)
Number of subjects: 181
Study 28930797 — intervention group
Group type: COMPARATOR
Intervention: Delayed everolimus (EVR-D)
Number of subjects: 181
Study 26327289 — intervention group
Group type: EXPERIMENTAL
Intervention: Local treatment focusing on quadriceps strengthening, quadriceps stretching, and taping for fortnight 1, supplemented with individualized global treatment focusing on lower limb posture and movement patterns for fortnight 2, followed by ongoing self-management.
Number of subjects: 37
Study 27129006 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir oral suspension (100 mg/mL, 6 mL) with low-dose ritonavir (100 mg, days 1-5)
Number of subjects: 38
Study 27129006 — intervention group
Group type: COMPARATOR
Intervention: Darunavir tablets (600 mg, 2 x 300 mg) with low-dose ritonavir (100 mg, days 1-5)
Number of subjects: 38
Study 27129006 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir oral suspension (600 mg) with low-dose ritonavir (100 mg, days 1-9)
Number of subjects: 38
Study 21862196 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled food challenge (DBPCFC) with hazelnut in 11 subjects
Number of subjects: 904
Study 21862196 — intervention group
Group type: COMPARATOR
Intervention: History of hazelnut allergy and/or positive skin tests
Number of subjects: 904
Study 21862196 — intervention group
Group type: COMPARATOR
Intervention: Prick-to-prick skin tests with fresh hazelnut
Number of subjects: 904
Study 21862196 — intervention group
Group type: COMPARATOR
Intervention: Overall skin test sensitisation to hazelnut
Number of subjects: 904
Study 20041911 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocinaplon 90 mg t.i.d.
Number of subjects: 60
Study 20041911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17670917 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification (LSM)
Number of subjects: 0
Study 17670917 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 17670917 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification and metformin
Number of subjects: 0
Study 17670917 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 15732092 — intervention group
Group type: EXPERIMENTAL
Intervention: BILN‐2061, 500 mg twice-daily for 2 days
Number of subjects: 10
Study 15732092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11874817 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (2 mg every 6 h, n = 71)
Number of subjects: 199
Study 11874817 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (30 mg every 12 h, n = 62)
Number of subjects: 199
Study 11874817 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 66)
Number of subjects: 199
Study 11874817 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of budesonide and prednisolone
Number of subjects: 199
Study 10232362 — intervention group
Group type: EXPERIMENTAL
Intervention: c-mpl ligands (recombinant thrombopoietin or pegylated megakaryocyte growth and development factor)
Number of subjects: 0
Study 10232362 — intervention group
Group type: EXPERIMENTAL
Intervention: c-mpl ligands
Number of subjects: 0
Study 8522634 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 20 mg once daily
Number of subjects: 483
Study 8522634 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 60 mg once daily
Number of subjects: 483
Study 8522634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 483
Study 8522634 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (20 mg and 60 mg)
Number of subjects: 483
Study 2347498 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training group
Number of subjects: 48
Study 2347498 — intervention group
Group type: COMPARATOR
Intervention: Social activity control group
Number of subjects: 48
Study 2347498 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group
Number of subjects: 48
Study 383011 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 27
Study 383011 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 27
Study 31444972 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with bevacizumab
Number of subjects: 0
Study 31444972 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy alone
Number of subjects: 0
Study 31444972 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy ± bevacizumab
Number of subjects: 0
Study 31444972 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive biomarkers
Number of subjects: 0
Study 28958110 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (50,000 IU every 2 weeks for 12 weeks)
Number of subjects: 60
Study 26682790 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-severe sleep-disordered breathing (SDB) determined by a 2-channel screening device (ApneaLink)
Number of subjects: 6876
Study 26682790 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-severe SDB in women
Number of subjects: 6876
Study 26682790 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-severe SDB in men
Number of subjects: 6876
Study 26682790 — intervention group
Group type: EXPERIMENTAL
Intervention: Age groups and prevalence of SDB
Number of subjects: 6876
Study 26682790 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (per 5 units)
Number of subjects: 6876
Study 26682790 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (per 5% decrement from 45%)
Number of subjects: 6876
Study 26682790 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (per 10-year difference to 60 years)
Number of subjects: 6876
Study 26682790 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 6876
Study 26682790 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 6876
Study 25634768 — intervention group
Group type: EXPERIMENTAL
Intervention: Early specific intervention program carried out by rheumatologists
Number of subjects: 123
Study 25634768 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control Group)
Number of subjects: 123
Study 25634768 — intervention group
Group type: EXPERIMENTAL
Intervention: Early specific intervention program
Number of subjects: 123
Study 23775099 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol foam (3%)
Number of subjects: 130
Study 23775099 — intervention group
Group type: COMPARATOR
Intervention: Liquid sclerotherapy (polidocanol 3%)
Number of subjects: 130
Study 20568428 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-step acupuncture combined with oral administration of Aspirin for six months
Number of subjects: 120
Study 20568428 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Aspirin alone
Number of subjects: 120
Study 20568428 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-step acupuncture combined with oral administration of Aspirin
Number of subjects: 120
Study 18843003 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 0
Study 18843003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16642971 — intervention group
Group type: EXPERIMENTAL
Intervention: Perforated Makrolon curtains placed in front of racks, with air ventilation through the corridor and holes in the curtain.
Number of subjects: 0
Study 14664898 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg/day (n=16)
Number of subjects: 150
Study 14664898 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day (n=16)
Number of subjects: 150
Study 14664898 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=16)
Number of subjects: 150
Study 10623698 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 473
Study 10623698 — intervention group
Group type: COMPARATOR
Intervention: Three cycles of CMF
Number of subjects: 473
Study 10623698 — intervention group
Group type: COMPARATOR
Intervention: Six cycles of CMF
Number of subjects: 473
Study 9124805 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal lobectomy
Number of subjects: 81
Study 9124805 — intervention group
Group type: COMPARATOR
Intervention: Continued medical management
Number of subjects: 81
Study 8455298 — intervention group
Group type: EXPERIMENTAL
Intervention: Soil and interior dust abatement and loose paint removal (study group)
Number of subjects: 152
Study 8455298 — intervention group
Group type: COMPARATOR
Intervention: Interior dust abatement and loose paint removal (comparison group A)
Number of subjects: 152
Study 8455298 — intervention group
Group type: COMPARATOR
Intervention: Only interior loose paint removal (comparison group B)
Number of subjects: 152
Study 3463726 — intervention group
Group type: EXPERIMENTAL
Intervention: Three different dentifrices
Number of subjects: 83
Study 29917215 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronised dispersible ferric pyrophosphate plus alpha-lactalbumin (MDFP-AL), 30 mg of MDFP-AL per day for 30 days
Number of subjects: 50